Glaxosmithkline Pharmaceuticals Limited Stock EBITDA
| GLAXO Stock | 2,414 28.15 1.18% |
GlaxoSmithKline Pharmaceuticals Limited fundamentals help investors to digest information that contributes to GlaxoSmithKline Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 8.9 B | 7.5 B |
GlaxoSmithKline | EBITDA |
GlaxoSmithKline Pharmaceuticals Limited Company EBITDA Analysis
GlaxoSmithKline Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current GlaxoSmithKline Pharmaceuticals EBITDA | 8.87 B |
Most of GlaxoSmithKline Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
GlaxoSmithKline Ebitda
Ebitda |
|
According to the company disclosure, GlaxoSmithKline Pharmaceuticals Limited reported earnings before interest,tax, depreciation and amortization of 8.87 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all India stocks is 127.6% lower than that of the firm.
GlaxoSmithKline EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline Pharmaceuticals could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline Pharmaceuticals by comparing valuation metrics of similar companies.GlaxoSmithKline Pharmaceuticals is currently under evaluation in ebitda category among its peers.
GlaxoSmithKline Fundamentals
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 382.29 B | ||||
| Shares Outstanding | 169.41 M | ||||
| Shares Owned By Insiders | 75.58 % | ||||
| Shares Owned By Institutions | 8.46 % | ||||
| Price To Book | 24.16 X | ||||
| Price To Sales | 11.48 X | ||||
| Revenue | 34.54 B | ||||
| Gross Profit | 19 B | ||||
| EBITDA | 8.87 B | ||||
| Net Income | 5.9 B | ||||
| Total Debt | 186.65 M | ||||
| Book Value Per Share | 97.18 X | ||||
| Cash Flow From Operations | 5.82 B | ||||
| Earnings Per Share | 39.84 X | ||||
| Target Price | 2914.5 | ||||
| Number Of Employees | 3.21 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 408.88 B | ||||
| Total Asset | 35.57 B | ||||
| Retained Earnings | 16.35 B | ||||
| Working Capital | 12.73 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 35.57 B |
About GlaxoSmithKline Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline Pharmaceuticals financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline Pharmaceuticals security.